<p>BiomX Inc. announced the discontinuation of its Phase 2b clinical trial of BX004 for the treatment of Cystic Fibrosis associated with chronic Pseudomonas aeruginosa infections. The decision followed an evaluation of projected timelines and resources required to proceed with an alternative dosing strategy recommended by an independent Data Monitoring Committee, which were determined to be beyond the company’s available resources. BiomX will implement cost-cutting measures, including a significant reduction of its workforce. The company will now focus on advancing its bacteriophage-based therapeutic candidate BX011 for diabetic foot infections, subject to the availability of sufficient financial and other resources, and is reviewing other strategic alternatives. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BiomX Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-25-118969), on December 08, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT) Original Document: here</p>

PHGE

<p>BiomX Inc. has discontinued its Phase 2b clinical trial of BX004 for Cystic Fibrosis due to resource constraints. The company will cut costs by reducing its workforce and focus on advancing BX011 for diabetic foot infections, pending financial resources. BiomX is also reviewing other strategic alternatives.</p>

BiomX Discontinues Cystic Fibrosis Program and Reduces Workforce